000877865 001__ 877865
000877865 005__ 20210130005256.0
000877865 0247_ $$2doi$$a10.2967/jnumed.119.234898
000877865 0247_ $$2ISSN$$a0022-3123
000877865 0247_ $$2ISSN$$a0097-9058
000877865 0247_ $$2ISSN$$a0161-5505
000877865 0247_ $$2ISSN$$a1535-5667
000877865 0247_ $$2ISSN$$a2159-662X
000877865 0247_ $$2Handle$$a2128/25224
000877865 0247_ $$2altmetric$$aaltmetric:68999734
000877865 0247_ $$2pmid$$apmid:31628219
000877865 0247_ $$2WOS$$aWOS:000530836100024
000877865 037__ $$aFZJ-2020-02483
000877865 082__ $$a610
000877865 1001_ $$0P:(DE-HGF)0$$aDietlein, Felix$$b0
000877865 245__ $$aIntraindividual Comparison of 18 F-PSMA-1007 with Renally Excreted PSMA Ligands for PSMA PET Imaging in Patients with Relapsed Prostate Cancer
000877865 260__ $$aNew York, NY$$bSoc.$$c2020
000877865 3367_ $$2DRIVER$$aarticle
000877865 3367_ $$2DataCite$$aOutput Types/Journal article
000877865 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1594038974_25319
000877865 3367_ $$2BibTeX$$aARTICLE
000877865 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000877865 3367_ $$00$$2EndNote$$aJournal Article
000877865 520__ $$a18F-prostate-specific membrane antigen (PSMA)-1007 is excreted mainly through the liver. We benchmarked the performance of 18F-PSMA-1007 against 3 renally excreted PSMA tracers. Methods: Among 668 patients, we selected 27 in whom PET/CT results obtained with 68Ga-PSMA-11, 18F-DCFPyL (2-(3-(1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl)-ureido)-pentanedioic acid), or 18F-JK-PSMA-7 (JK, Juelich-Koeln) were interpreted as equivocal or negative or as oligometastatic disease (PET-1). Within 3 wk, a second PET scan with 18F-PSMA-1007 was performed (PET-2). The confidence in the interpretation of PSMA-positive locoregional findings was scored on a 5-point scale, first in routine diagnostics (reader 1) and then by an independent second evaluation (reader 2). Discordant PSMA-positive skeletal findings were examined by contrast-enhanced MRI. Results: For both readers, 18F-PSMA-1007 facilitated the interpretability of 27 locoregional lesions. In PET-2, the clinical readout led to a significantly lower number of equivocal locoregional lesions (P = 0.024), and reader 2 reported a significantly higher rate of suspected lesions that were falsely interpreted as probably benign in PET-1 (P = 0.023). Exclusively in PET-2, we observed a total of 15 PSMA-positive spots in the bone marrow of 6 patients (22%). None of the 15 discordant spots had a morphologic correlate on the corresponding CT scan or on the subsequent MRI scan. Thus, 18F-PSMA-1007 exhibits a significantly higher rate of unspecific medullary spots (P = 0.0006). Conclusion: 18F-PSMA-1007 may increase confidence in interpreting small locoregional lesions adjacent to the urinary tract but may decrease the interpretability of skeletal lesions. 
000877865 536__ $$0G:(DE-HGF)POF3-573$$a573 - Neuroimaging (POF3-573)$$cPOF3-573$$fPOF III$$x0
000877865 588__ $$aDataset connected to CrossRef
000877865 7001_ $$0P:(DE-HGF)0$$aKobe, Carsten$$b1
000877865 7001_ $$0P:(DE-HGF)0$$aHohberg, Melanie$$b2
000877865 7001_ $$0P:(DE-Juel1)176188$$aZlatopolskiy, Boris D.$$b3
000877865 7001_ $$0P:(DE-Juel1)169356$$aKrapf, Philipp$$b4$$ufzj
000877865 7001_ $$0P:(DE-Juel1)180330$$aEndepols, Heike$$b5$$ufzj
000877865 7001_ $$0P:(DE-HGF)0$$aTäger, Philipp$$b6
000877865 7001_ $$0P:(DE-Juel1)184744$$aHammes, Jochen$$b7$$ufzj
000877865 7001_ $$0P:(DE-HGF)0$$aHeidenreich, Axel$$b8
000877865 7001_ $$0P:(DE-HGF)0$$aPersigehl, Thorsten$$b9
000877865 7001_ $$0P:(DE-Juel1)166419$$aNeumaier, Bernd$$b10$$ufzj
000877865 7001_ $$0P:(DE-Juel1)177611$$aDrzezga, Alexander$$b11$$ufzj
000877865 7001_ $$0P:(DE-HGF)0$$aDietlein, Markus$$b12$$eCorresponding author
000877865 773__ $$0PERI:(DE-600)2040222-3$$a10.2967/jnumed.119.234898$$gVol. 61, no. 5, p. 729 - 734$$n5$$p729 - 734$$tJournal of nuclear medicine$$v61$$x2159-662X$$y2020
000877865 8564_ $$uhttps://juser.fz-juelich.de/record/877865/files/Autorenversion.pdf$$yOpenAccess
000877865 8564_ $$uhttps://juser.fz-juelich.de/record/877865/files/Autorenversion.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000877865 909CO $$ooai:juser.fz-juelich.de:877865$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000877865 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)169356$$aForschungszentrum Jülich$$b4$$kFZJ
000877865 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)180330$$aForschungszentrum Jülich$$b5$$kFZJ
000877865 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)184744$$aForschungszentrum Jülich$$b7$$kFZJ
000877865 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)166419$$aForschungszentrum Jülich$$b10$$kFZJ
000877865 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)177611$$aForschungszentrum Jülich$$b11$$kFZJ
000877865 9131_ $$0G:(DE-HGF)POF3-573$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$vNeuroimaging$$x0
000877865 9141_ $$y2020
000877865 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-01-18
000877865 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-01-18
000877865 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-01-18
000877865 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2020-01-18
000877865 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-01-18
000877865 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NUCL MED : 2018$$d2020-01-18
000877865 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-01-18
000877865 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index$$d2020-01-18
000877865 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-01-18
000877865 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000877865 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ NUCL MED : 2018$$d2020-01-18
000877865 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2020-01-18
000877865 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-01-18
000877865 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-01-18
000877865 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-01-18
000877865 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-01-18
000877865 920__ $$lyes
000877865 9201_ $$0I:(DE-Juel1)INM-5-20090406$$kINM-5$$lNuklearchemie$$x0
000877865 9201_ $$0I:(DE-Juel1)INM-2-20090406$$kINM-2$$lMolekulare Organisation des Gehirns$$x1
000877865 980__ $$ajournal
000877865 980__ $$aVDB
000877865 980__ $$aUNRESTRICTED
000877865 980__ $$aI:(DE-Juel1)INM-5-20090406
000877865 980__ $$aI:(DE-Juel1)INM-2-20090406
000877865 9801_ $$aFullTexts